Litts Drug Eruption & Reaction Database - Presented by CRC Press

Nothing else can remotely compare to it.Patricia Wong, MD, Stanford University Medical Centre


Log in
In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Continue
Menu
Login
  • Home
  • About About
    • About the Database
    • About the Book
    • Related Products
    • About Dr Litt
    • About Dr Shear
  • Alerts
  • Litt’s App
  • Contact Us
  • Help
  • Subscribe Subscribe
    • Individual Subscription
    • Institutional Subscription

Drugs belonging to  restart save

class – Cyclin-dependent kinase (CDK) 4/6 inhibitor – 4 items found

  • show all
  • 0–9
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Abemaciclib

Palbociclib

Ribociclib

Trilaciclib


Loading more results

No more results to show

Adverse reactions attributed to entire drug class 'Cyclin-dependent kinase (CDK) 4/6 inhibitor'

Please login to view adverse reactions.

Bullous skin rash

    • (2024): Ortiz-Brugués A+, Ann Oncol 35(10), 915-917

Vitiligo

    • (2021): Sollena P+, Breast Cancer Res Treat 185(1), 247-253 (16 cases)

Alopecia / hair loss

    • (2023): Minta A+, Support Care Cancer 31(12), 717

Cardiovascular adverse effect (includes major adverse cardiovascular events (MACE))

    • (2024): Zhang C+, Am J Cardiovasc Drugs Dec, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)

Venous thromboembolism

    • (2020): Gervaso L+, J Thromb Haemost 18(1), 162-168 [REVIEW]

Anorexia

Hypertransaminasemia (hepatic transaminitis) / elevated transaminases

    • (2020): Kovac A+, Cancer Treat Res Commun Aug, Online ahead of print6% (grade 3–4)

Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)

    • (2024): She Y+, Front Pharmacol Apr (e-Collection) (pharmacovigilance / pharmacoepidemiology)

Hemotoxicity

    • (2018): Kassem L+, Breast Cancer 25(1), 17 [REVIEW]

Leukocytopenia (leukopenia) / leukocytes (white blood cells) decreased

    • (2023): Peng TR+, Thorac Cancer Sep, Online ahead of print45%

Neutropenia (neutrophils decreased)

    • (2020): Kovac A+, Cancer Treat Res Commun Aug, Online ahead of print50% (grade 3–4)

Arthralgia

    • (2021): Andrikopoulou A+, Cancers (Basel) 13(3), 4656–33% [REVIEW] (with an aromatase inhibitor)

Asthenia / fatigue

    • (2023): Peng TR+, Thorac Cancer Sep, Online ahead of print51%

Back pain

    • (2021): Andrikopoulou A+, Cancers (Basel) 13(3), 4653–9% [REVIEW] (with an aromatase inhibitor)

Bone pain / joint pain

    • (2021): Andrikopoulou A+, Cancers (Basel) 13(3), 4653–9% [REVIEW] (with an aromatase inhibitor)

Myalgia/Myositis/Myopathy/Myotoxicity

    • (2021): Andrikopoulou A+, Cancers (Basel) 13(3), 4655–12% [REVIEW] (with an aromatase inhibitor)

Interstitial lung disease / interstitial pneumonitis / interstitial pneumonia (cryptogenic organizing pneumonia) / drug-induced interstitial lung disease

    • (2023): Schlam I+, Expert Opin Drug Saf 22(12), 1149-1156 [REVIEW]
    • (2021): Raschi E+, Breast Cancer Res Treat 186(1), 219-227 (pharmacovigilance / pharmacoepidemiology)

Pulmonary toxicity

    • (2019): Jazieh KA+, Expert Rev Anticancer Ther 19(11), 917-919 [REVIEW]

Adverse effects / adverse reactions

    • (2024): Wekking D+, Semin Oncol Jan, Online ahead of print [REVIEW]

Saved Searches Watched Drugs
Litt's app available free to subscribers

Search drug eruptions and reactions data anytime, anywhere

With full access to drug profiles, reactions and linked PubMed abstracts through your smart phone!

If you subscribe via your institution and do not have a personal login you will need to register on the website to create a login for the app.

Back to top
  • Help
  • Terms & Conditions
  • Privacy
  • Disclaimer
  • Contact us

© 2025 Taylor & Francis Group, LLC. All Rights Reserved.